Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach

dc.contributor.author	Mutlu, O.
dc.contributor.author	Ugurel, O.M.
dc.contributor.author	Sariyer, E.
dc.contributor.author	Ata, O.
dc.contributor.author	Inci, T.G.
dc.contributor.author	Ugurel, E.
dc.contributor.author	Kocer, S.
dc.contributor.author	Turgut-Balik, D.
dc.date.accessioned	2021-12-21T08:40:49Z
dc.date.available	2021-12-21T08:40:49Z
dc.date.issued	2020
dc.identifier.issn	7391102
dc.identifier.uri	https://doi.org/10.1080/07391102.2020.1819882
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1207
dc.description.abstract	In this study, the Nsp12–Nsp8 complex of SARS-CoV-2 was targeted with structure-based and computer-aided drug design approach because of its vital role in viral replication. Sequence analysis of RNA-dependent RNA polymerase (Nsp12) sequences from 30,366 d
dc.language.iso	English
dc.publisher	Taylor and Francis Ltd.
dc.rights	All Open Access, Bronze, Green
dc.title	Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach
dc.type	Article
dc.relation.journal	Journal of Biomolecular Structure and Dynamics
dc.identifier.doi	10.1080/07391102.2020.1819882

Files in this item

Files	Size	Format	View
There are no files associated with this item.